LUDWIG - Key Persons
Job Titles:
- Executive Assistant / Professional Services Role
As the Executive Assistant to the Director, I provide executive support to the Director and oversee the running of the Director's office, also working closely with her lab and the wider Institute.
Job Titles:
- Operations Administrator
- HR, Internships
As Operations Manager, I deal with various administrative tasks including student admin and HR.
I provide computers and software for staff and students at the Ludwig Institute and manage some additional software systems.
I head the computational genomics group at the Ludwig Institute for Cancer Research.
The main focus of my group is to understand the causes and consequences of mutation rate heterogeneity. In previous work, I established that epigenetic marks in the form of histone modifications have a profound influence on the mutational landscape in cancer cells. More recently, my lab analysed the influence of different DNA modifications on mutability, and described how DNA replication changes the distribution of mutations in cancer genomes. This has important implications for our understanding of cancer development. For example, it allows us to identify new carcinogenic mechanisms that might be preventable.
We are also interested in developing novel genomic methods in the area of single-cell technology. For example, as part of ongoing collaboration we have created tools to assess the robustness of single-cell transcriptome measurements, and built tools to process epigenetic sequencing data using a brand-new, Oxford-developed technology called TAPS.
Job Titles:
- Professor of Tumour Immunology
I am an expert in tumour immunology (MD, PhD) and I am currently a Member of the Ludwig Institute for Cancer Research and Director of the de Duve Institute, Belgium. I am also Full Professor of Immunology at the Université catholique de Louvain in Brussels and I train young scientists, including PhD students, medical students and postdoctoral Fellows from all over the world. I serve as member of several national and international scientific committees and editorial boards, and I am a full member of the Belgian Royal Academy of Medicine.
I initially identified, together with Thierry Boon, the first tumour rejection antigen naturally expressed by mouse tumours and recognised by CD8 T lymphocytes. I subsequently identified a number of human tumour antigens recognised by CD8 T lymphocytes and I studied their processing, i.e. how they are produced by the cell. This led to the discovery of peptide splicing by the proteasome and of novel proteasome subtypes. I also described how tumours resist immune rejection by degrading tryptophan, through the expression of indoleamine dioxygenase (IDO) or tryptophan dioxygenase (TDO).
I am co-founder of iTeos Therapeutics, a biotechnology company based in Gosselies (Belgium) launched in 2012 as a spin-off of Ludwig Cancer Research. Its activity consists in developing small molecule immunomodulators for cancer treatment. Its first compound, an IDO inhibitor, is at the stage of clinical testing in cancer patients.
In 2016, I started a second group at Ludwig Oxford, to develop synergies in the tumour immunology landscape, focusing on cancer vaccines. I am also Professor of Tumour Immunology at the University of Oxford.
I have published more than 175 scientific papers and books and given more than 150 invited lectures at international meetings. My work has been cited more than 15,000 times in the scientific literature.
Job Titles:
- Associate Professor of Haematology
Job Titles:
- Research Integrity and Communications Officer / Support
I completed a PhD in virology at the National Institute for Medical Research, London, UK. I then did postdoctoral work in Pierre Chambon's lab in Strasbourg, France, where I developed an interest in transcription regulation before taking up a position at the Marie Curie Research Institute, Oxted, UK, to continue working on gene regulation, both in S. cerevisiae, as well as in melanocytes and melanoma. In 2008, I moved to the Ludwig Institute, where I continue to examine the role of signalling and transcription in melanoma biology, with the aim of developing novel and anti-cancer therapies that take tumour phenotypic heterogeneity into account.
Job Titles:
- Branch Administrator
- Business Manager / Professional Services Role
- Finance, Grants & Operations )
II am a business manager at the University of Oxford, supporting the Ludwig Institute for Cancer Research. As the BM of the branch, I provide operational, financial and strategic support to the Institute. During my career in administration, I have also provided management support to other NDM units such as The Centre for Human Genetics and The Jenner Institute.
Job Titles:
- Professor of Hepatology and Experimental Medicine
Job Titles:
- Professor of Mathematical Biology
Job Titles:
- Professor of Engineering Science
Job Titles:
- Visiting Professor in Cancer Immunotherapy
Job Titles:
- Master of Daydreams
- Professor of Clinical Medicine
Job Titles:
- Professor of Cancer Signalling
Job Titles:
- Visiting Professor of Cancer Epigenetics